نشریه

The aim of this study was to investigate the improvements of central serous chorioretinopathy (CSC) treated with topical dorzolamide. These observational case studies included nine eyes of the nine patients with CSC, treated by a physician with topical dorzolamide consecutively over a one-month period. The central macular thickness and best-corrected visual acuity (BCVA) were measured and compared with baseline values. All the eyes of nine patients demonstrated subretinal fluid (SRF) before or during the treatment course. The SRF was measured and compared with baseline values in this subgroup. Among the cases (n=9), the mean age was reported as 39±6, and BCVA improved in 77% (7 cases), 11.1% (1 case), and 11.1% (1 case) of the cases within two, four, and ten weeks of treatment after the follow-ups, respectively. Indeed, the mean value of central macular thickness showed improvement from 4.72±1.40 to 3.93±9.8 microns (P=0.211). The SRF decreased during follow-up treatment with the mean time of 0.7±0.6 months; however, central macular thickness, choroidal thickness, and BCVA revealed no significant change. Topical dorzolamide might improve BCVA and decrease SRF in patients with CSC. This case series study demonstrated that topical dorzolamide might be effective in the treatment of CSC.